These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide. Tulley JM; Palmer JL; Gamelli RL; Faunce DE Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934 [TBL] [Abstract][Full Text] [Related]
50. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755 [TBL] [Abstract][Full Text] [Related]
51. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803 [TBL] [Abstract][Full Text] [Related]
52. Application of natural killer T cells in antitumor immunotherapy. Hong C; Park SH Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797 [TBL] [Abstract][Full Text] [Related]
53. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223 [TBL] [Abstract][Full Text] [Related]
54. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. Biburger M; Tiegs G J Immunol; 2005 Aug; 175(3):1540-50. PubMed ID: 16034092 [TBL] [Abstract][Full Text] [Related]
55. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines. Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862 [TBL] [Abstract][Full Text] [Related]
56. The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions. Macho-Fernandez E; Brigl M Front Immunol; 2015; 6():362. PubMed ID: 26284062 [TBL] [Abstract][Full Text] [Related]
57. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids. Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115 [TBL] [Abstract][Full Text] [Related]
58. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316 [TBL] [Abstract][Full Text] [Related]